Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary.

CONCLUSION: During the 2 years bid (public procurement procedure), the National Health Insurance Fund Administration managed to reduce the health insurance subsidy paid for the reimbursement of both original and biosimilar G-CSF products by 3.89 billion HUF (14.7 million EUR) or 51.9 % without significant changes in the number of patients having access to treatment. PMID: 30763134 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research